Statements (59)
Predicate | Object |
---|---|
gptkbp:instanceOf |
monoclonal antibody
|
gptkbp:administrativeDivision |
infusion
every 2 weeks |
gptkbp:analyzes |
cancer patients
|
gptkbp:barrelLength |
high
|
gptkbp:clinicalTrials |
gptkb:United_States
gptkb:Xencor Phase 1 pending Phase 2 open-label study |
gptkbp:collaborations |
various research institutions
|
gptkbp:community_service |
overall survival
progression-free survival safety and tolerability |
gptkbp:compatibleWith |
immune modulation
|
gptkbp:contraindication |
gptkb:melanoma
renal cell carcinoma non-small cell lung cancer |
gptkbp:currentStatus |
completed
|
gptkbp:developedBy |
gptkb:Xencor
|
gptkbp:dosageForm |
weight-based dosing
|
gptkbp:evaluates |
under investigation
|
gptkbp:formulation |
liquid
|
gptkbp:hasPopulation |
advanced cancer patients
|
gptkbp:historicalResearch |
recombinant DNA technology
|
https://www.w3.org/2000/01/rdf-schema#label |
XmAb18087
|
gptkbp:market |
high
|
gptkbp:patentAssignee |
gptkb:Xencor,_Inc.
|
gptkbp:patentStatus |
patented
|
gptkbp:productionCompany |
clinical trials
|
gptkbp:purpose |
cancer immunotherapy
|
gptkbp:regulatoryCompliance |
investigational new drug
|
gptkbp:relatedTo |
immune system
|
gptkbp:releaseYear |
2015
|
gptkbp:research |
public and private sources
biopharmaceutical research |
gptkbp:research_areas |
monoclonal antibodies
immunotherapy |
gptkbp:researchAndDevelopment |
quality of life improvement
tumor shrinkage improved immune response prolonged survival biomarker_identification |
gptkbp:researchFocus |
oncology
|
gptkbp:researchInterest |
academic institutions
peer-reviewed journals |
gptkbp:route |
intravenous
|
gptkbp:safetyFeatures |
under evaluation
|
gptkbp:sideEffect |
immune-related adverse events
|
gptkbp:status |
in development
|
gptkbp:storage |
refrigerated
|
gptkbp:targets |
T cells
PD-1 PD-1 pathway inhibition various solid tumors |
gptkbp:triggerType |
immune checkpoint inhibition
blocks PD-1 receptor |
gptkbp:usedFor |
cancer treatment
|